Fig. 4

Rates of GFAP and NfL change across prodromal and symptomatic phases. a,b For individuals with one or more serial GFAP (a) or NfL (b) measurements at least one year from baseline, we show comparisons of rate of change in biomarker concentrations per year for controls, all presymptomatic mutation carriers combined (All PreSx), presymptomatic carriers who did not convert (Non-conv), those that did phenoconvert (Phenoconv) and participants with MBCI, bvFTD, PPA or parkinsonian disorders. The number of participants (n) is shown. p values are from analysis adjusted for age and sex when comparing rates of GFAP or NfL change between controls and the indicated groups. p < 0.0071 is considered statistically significant; ****p < 0.0001, *** p < 0.001 and **p < 0.01. See also Table S19